These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2974757)

  • 1. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma.
    Kjaer M
    Cancer Treat Rev; 1988 Sep; 15(3):195-209. PubMed ID: 2974757
    [No Abstract]   [Full Text] [Related]  

  • 2. Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.
    Tomic R; Ljungberg B; Damber JE
    Scand J Urol Nephrol Suppl; 1988; 110():185-7. PubMed ID: 2973122
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase II study.
    Kjaer M; Frederiksen PL
    Cancer Treat Rep; 1986 Mar; 70(3):431-2. PubMed ID: 2937534
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of high dose medroxyprogesterone acetate treatment on antithrombin III and other plasma proteins in males with renal cell or prostatic carcinoma.
    Nilsson TK; Tomic R; Ljungberg B
    Scand J Urol Nephrol; 1989; 23(1):11-4. PubMed ID: 2522237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Deoxyribonucleic acid content and medroxyprogesterone acetate treatment in metastatic renal cell carcinoma.
    Neuwirth H; Blyth B; Richie AW; Taube DM; deKernion JB
    J Urol; 1990 Sep; 144(3):749-50. PubMed ID: 2143789
    [No Abstract]   [Full Text] [Related]  

  • 6. Nuclear androgen receptor as marker of responsiveness to medroxyprogesterone acetate in human renal cell carcinoma.
    Concolino G; Marocchi A; Toscano V; Di Silverio F
    J Steroid Biochem; 1981 Dec; 15():397-402. PubMed ID: 6461800
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of medroxyprogesterone acetate and doxorubicin on sublines of 13762 mammary adenocarcinoma in rats.
    Formelli F; Zaccheo T; Casazza AM; Bellini O; Di Marco A
    Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1211-21. PubMed ID: 6460631
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of rat prostatic adenocarcinoma with medroxyprogesterone acetate (MPA): effects on growth and morphology.
    Damber JE; Bergh A; Landström M; Tomić R
    J Urol; 1991 Jun; 145(6):1283-7. PubMed ID: 1827847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scintigraphic evidence for the regression of skeletal metastases from a hypernephroma following long-term treatment with medroxyprogesterone acetate.
    Minervini R; Fiorentini L; Carlino F; Mazzuca N; Mariani G
    J Nucl Med Allied Sci; 1982; 26(1):55-9. PubMed ID: 6213743
    [No Abstract]   [Full Text] [Related]  

  • 10. Advanced adenocarcinoma of the kidney: therapy with lomustine, vinblastine, hydroxyurea, and medroxyprogesterone acetate and regression analysis of factors relating to survival.
    Brubaker LH; Troner MB; Birch R
    Cancer Treat Rep; 1983; 67(7-8):741-2. PubMed ID: 6223695
    [No Abstract]   [Full Text] [Related]  

  • 11. Calcification of humeral metastasis of renal adenocarcinoma 8 months after medroxyprogesterone acetate therapy.
    Scanni A; Riundi R; Vezzoni MA; Canigiula L
    J Urol; 1984 May; 131(5):984. PubMed ID: 6231386
    [No Abstract]   [Full Text] [Related]  

  • 12. [Experiences with Depo-Provera (medroxyprogesterone) in the treatment of kidney tumors].
    Balogh F; Romics I
    Z Urol Nephrol; 1987 Aug; 80(8):449-53. PubMed ID: 2961162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinovir treatment of adenocarcinoma of the uterus with lung metastases].
    Stertmann WA; Hocke M; Röttger P
    MMW Munch Med Wochenschr; 1983 Jul; 125(29-30):685-6. PubMed ID: 6225946
    [No Abstract]   [Full Text] [Related]  

  • 14. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma.
    Rendina GM; Donadio C; Fabri M; Mazzoni P; Nazzicone P
    Eur J Obstet Gynecol Reprod Biol; 1984 Jun; 17(4):285-91. PubMed ID: 6235140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of disseminated breast cancer successfully treated with medroxyprogesterone acetate].
    Tsumura I; Okamura Y; Takatsuka Y; Kobayakawa K; Kawahara T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1509-12. PubMed ID: 2143889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of skeletal metastases from hypernephroma following long-term treatment with medroxyprogesterone acetate.
    Minervini R; Fiorentini L; Carlino F; Mariani G
    J Urol; 1982 Sep; 128(3):605-6. PubMed ID: 6214644
    [No Abstract]   [Full Text] [Related]  

  • 17. [the oral use of a progestational hormone (Provera 100) as an adjuvant in therapy of adenocarcinoma of the kidney. Preliminary report].
    Liberti M; Di Silverio F; Concolino G; Tenaglia R; Marocchi A
    Minerva Urol; 1980; 32(3):175-8. PubMed ID: 7432332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative prophylactic use of progesterone in renal cell carcinoma.
    Satomi Y; Takai S; Kondo I; Fukushima S; Furuhata A
    J Urol; 1982 Nov; 128(5):919-22. PubMed ID: 6217352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with hormone receptors in renal cancer.
    Romics I; Rüssel C; Bach D
    Int Urol Nephrol; 1990; 22(6):507-12. PubMed ID: 1965539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive medroxyprogesterone acetate to radical nephrectomy in category M0 renal cell carcinoma. Preliminary report of a prospective randomized trial.
    Pizzocaro G; Di Fronzo G; Piva L; Salvioni R; Ronchi E; Cappelletti V; Giongo A; Mastroberardino E; Cozzoli C; Dormia E; Minervini S; Zanollo A; Fontanella U; Giannoni R; Maggioni A; Lasio E
    Eur Urol; 1983; 9(4):202-6. PubMed ID: 6223819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.